TOMI study shows pathogen reduction in food processing
TOMI Environmental Solutions (TOMZ) reported that its SteraMist iHP product significantly reduced Listeria monocytogenes in food processing facilities, according to an independent study. The treatment achieved over 7 log reduction on flat surfaces and over 3 log on equipment parts. The global food sanitation market is projected to grow to $17.4B by 2035, according to Global Market Insights.
How this was made
The 30-second read
Why it matters
The new study provides the first independent validation of its SteraMist iHP product against Listeria, a major food‑borne pathogen, potentially opening new contracts in food processing.
Market read
The study could boost TOMZ's visibility and lead to new sales, but scale and execution remain uncertain.
What to watch
The study does not address cost, regulatory approvals, or competitive landscape, which could limit adoption.
Background
TOMI Environmental Solutions (NASDAQ:TOMZ) develops binary ionization technology for disinfection across multiple sectors.
Ticker impact
TOMI Environmental Solutions released an independent lab study showing its SteraMist iHP product reduced Listeria monocytogenes by >7 log on flat surfaces.
potential upside as investors price in the new efficacy data and possible contract wins in food safety.
Novel efficacy results address a key pain point for food processors; no prior data existed, but the company is small and the market impact may be limited.
Market effects
Highlights growing demand for advanced sanitation solutions in food processing, may benefit peers in industrial hygiene.
U.S. food safety regulators may reference the data, but immediate regional effect is limited.
Shows potential for broader adoption of ionized hydrogen peroxide technology worldwide.
Counterpoint
Efficacy in lab settings may not translate to commercial scale; investors should weigh execution risk.
Key entities
- CompanyTOMI Environmental Solutions, Inc.
Developer of SteraMist iHP disinfection technology.
- IndividualJosh Hasty, Ph.D.
CEO of FH Services, partner to commercialize the study data.

